Solrikitug Shows Strong Results in Esophagus Trial

Uniquity Bio's phase 2 ALAMERE trial reports positive topline results for solrikitug in adults with eosinophilic esophagitis.

Updated on Nov. 18, 2026 in Allergies

Clean glass vials in a wooden rack beside a steel laboratory microscope on a white bench in a bright research lab.
Uniquity Bio reported positive topline phase 2 results for solrikitug in adults with eosinophilic esophagitis, meeting co-primary and key secondary endpoints versus placebo at week 24. AI Illustration. Upload story photo >

Uniquity Bio announced positive topline results from the ALAMERE phase 2 trial of solrikitug, a monoclonal antibody, in adults with eosinophilic esophagitis (EoE). The drug met its co-primary and key secondary endpoints versus placebo at week 24 across all doses tested and was well tolerated.

Why it matters

EoE is a chronic inflammatory condition of the esophagus driven by an allergic immune response, and its prevalence has risen roughly five-fold since 2009. Solrikitug targets thymic stromal lymphopoietin (TSLP), and the results support a planned pivotal phase 3 program that could provide clinical evidence for a regulatory filing.

The phase 2 trial's placebo-corrected histologic remission rates of 69%-76% at week 24 and dysphagia reductions of 8.8-12.6 points are topline figures from a randomized, double-blind, placebo-controlled study. Durability beyond week 24 and full data presentation remain pending as participants are tracked out to 52 weeks.

The players

Uniquity Bio

Uniquity Bio is a biopharmaceutical company developing solrikitug for allergic and inflammatory conditions, including eosinophilic esophagitis.

Merck & Co., Inc.

Merck & Co., Inc. is a global pharmaceutical company that in-licensed solrikitug to Uniquity Bio.

The details

ALAMERE was a randomized, double-blind, placebo-controlled trial evaluating solrikitug at three doses in adults with EoE, administered subcutaneously every four weeks. Uniquity Bio reported statistically significant results on co-primary and key secondary endpoints, with the drug well tolerated across all dose levels.

Timeline

  1. Week 24: primary efficacy endpoints measured in the ALAMERE trial.

  2. Week 52: planned follow-up for durability and safety.

  3. First quarter of 2027: planned initiation of a phase 3 trial of solrikitug.

  4. Early 2027: company expects to begin its pivotal phase 3 trial.

Big Picture

Solrikitug belongs to the TSLP-blocking antibody class, extending the approach used in allergic disease into eosinophilic esophagitis. Its phase 2 data add to the evidence that targeting this upstream cytokine can reduce esophageal inflammation.

For people living with EoE, the trial suggests a future treatment option that could reduce esophageal inflammation and dysphagia symptoms. The drug remains investigational, and no approved therapy or timeline for availability has been established.

The takeaway

Positive phase 2 data are an early step, and the pivotal phase 3 trial will determine whether solrikitug can become an approved option. Readers with EoE symptoms should discuss current management options with their clinician.

What happens next

Uniquity Bio plans to begin a pivotal phase 3 trial of solrikitug in the first quarter of 2027, with full ALAMERE results to be presented at a future medical congress.

Further reading

Explore more on Allergies to see how allergic immune responses drive conditions like eosinophilic esophagitis.

Source note: This article includes information reported by Pharmabiz.